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The overwhelming share of the global human immunodeficiency virus (HIV) infection and disease burden is
borne by resource-limited countries. The explosive spread of HIV infection and growing burden of disease in
these countries has intensified the need to find solutions to improved access to treatment for HIV infection.
The epidemic of HIV infection and acquired immune deficiency syndrome (AIDS) has been accompanied by
a severe epidemic of tuberculosis. Tuberculosis has become the major cause of morbidity and mortality in
patients with HIV disease worldwide. Among the various models of provision of HIV/AIDS care, one logical
but unexplored strategy is to integrate HIV/AIDS and tuberculosis care and treatment, including highly active
antiretroviral therapy, through existing tuberculosis directly observed therapy programs. This strategy could
address the related issues of inadequate access and infrastructure and need for enhanced adherence to med-
ication and thereby potentially improve the outcome for both diseases.
The overwhelming share of the global burden of HIV
infection and disease is borne by resource-limited coun-
tries. Of the worldwide total of 142 million people
living with HIV/AIDS at the end of 2002, close to 30
million were in sub-Saharan Africa and 16 million in
Southeast Asia [1]. In South Africa alone, 15.3 million
persons, or 1 in 4 adults, are currently thought to be
living with HIV/AIDS. The explosive spread of HIV
infection and growing burden of disease in Africa and
other resource-poor areas has intensified the need to
find solutions to improved access to treatment for HIV
infection.
Treatment of HIV infection with HAART has dra-
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matically altered the natural history of HIV disease
among those in resource-rich countries, for whom po-
tent combinations of antiretroviral agents have been
available. Of the millions of people worldwide eligible
for treatment, it is estimated that only 300,000 people
in resource-limited countries are receiving HAART, and
one-half of these are in Brazil, where universal access
has been established. Excessive cost and lack of infra-
structure and political will have limited access to
HAART in resource-poor countries. Requirements for
successful treatment of HIV infection with HAART in-
clude the existence of an HIV/AIDS care infrastructure
capable of identifying and caring for those with HIV
infection, providing a reliable source of medication,
maintaining support for adherence to probable lifelong
treatment, and monitoring of drug toxicities, side ef-
fects, and treatment response [2]. Recent reductions in
the prices of antiretroviral agents will make their avail-
ability more widespread. But even if drugs became uni-
versally available, the health care infrastructure needed
for their successful use is limited and must be rapidly
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expanded and put into place, lest the great potential benefit of
therapy be wasted [3]. The need to develop simple and sus-
tainable strategies for delivery of HIV/AIDS care and therapy
to large numbers of patients in the context of the existing
underdeveloped health care delivery systems is a matter of great
urgency. Among the various models of provision of HIV/AIDS
care, one proposed strategy is to integrate HIV/AIDS and tu-
berculosis care [3–5]. Further expansion of this strategy to in-
clude the provision of HAART through existing tuberculosis
directly observed therapy (DOT) programs is logical and ap-
pealing and warrants rapid and careful evaluation. Here we
explore the rationale and potential benefits and limitations of
such a strategy for resource-poor countries.
HIV/AIDS AND TUBERCULOSIS
Worldwide, the HIV/AIDS epidemic has been accompanied by
a severe epidemic of tuberculosis. It is estimated that there were
∼8 million new cases and 16 million prevalent cases of tuber-
culosis in 2000 [6]. The interaction between HIV and Myco-
bacterium tuberculosis has profoundly influenced the epide-
miology and clinical outcome of both diseases. HIV infection
markedly increases the risk of reactivation of latent tuberculosis
and of progression of primary disease after initial infection.
The lifetime risk for progressing to active tuberculosis among
HIV-negative persons latently infected with M. tuberculosis is
estimated to be 10% [7]. In contrast, among HIV-infected per-
sons, the risk is ∼10% per year. The risk for progressive primary
disease after recent infection with M. tuberculosis approaches
40% [8]. The global estimate of HIV coinfection in patients
with tuberculosis increased during the 1990s and reached 10%
by the end of the decade [6]. Although India has the greatest
absolute number of persons coinfected with HIV and M. tu-
berculosis, sub-Saharan Africa carries the greatest burden of the
global epidemic of tuberculosis associated with HIV infection,
with the highest proportion (32%) of patients with new cases
of tuberculosis who are coinfected with HIV [6]. An estimated
2 million adults are coinfected with HIV and M. tuberculosis
in South Africa alone [6], and in the province of KwaZulu
Natal, two-thirds of patients with newly diagnosed cases of
tuberculosis are coinfected with HIV [9].
Tuberculosis is the major medical complication of HIV dis-
ease and the major cause of death among people with AIDS
in resource-poor countries [4–6, 10]. HIV infection has a sub-
stantial deleterious impact on tuberculosis outcomes, and the
development of tuberculosis has been shown to accelerate the
course of HIV disease [11]. In the presence of HIV infection,
tuberculosis is associated with substantially higher case-fatality
rates regardless of use of effective tuberculosis chemotherapy
[12, 13]. Even though tuberculosis is treatable, the tuberculosis
case-fatality rate in some areas is very high, approaching 40%
at 1 year [14]. Among patients with tuberculosis who have
received antituberculosis therapy, most of the increased mor-
tality is directly attributable to untreated HIV infection and
associated opportunistic diseases and not to tuberculosis itself.
In addition to high mortality rates, the burden of HIV-as-
sociated tuberculosis on already weak health care facilities has
been immense. Tuberculosis programs are often unable to man-
age the increased numbers of HIV-related tuberculosis cases
and ensure completion of tuberculosis therapy, and inpatient
facilities are overwhelmed with patients with HIV infection and
tuberculosis. For example, a survey at the King Edward VIII
Hospital in Durban, KwaZulu Natal, South Africa, in 1998
reported that 54% of adult inpatients have an AIDS-related
illness, the majority of whom have pulmonary or extrapul-
monary tuberculosis [15].
DOT FOR TUBERCULOSIS
The importance of adherence to tuberculosis medications is
fundamental to treatment success. Poor adherence affects both
individual and public health and results in an increased mor-
bidity and mortality and the emergence and potential trans-
mission of multidrug resistance. DOT for tuberculosis was in-
troduced 140 years ago as a method of ensuring adherence to
medication, completion of treatment, and decreasing the risk
of development of drug-resistant tuberculosis, and it is the most
successful and well-studied of adherence interventions. This
strategy has become one of the central components of the
DOTS (directly observed therapy, short-course) strategy rec-
ommended by the World Health Organization (WHO) for
treatment of tuberculosis [16, 17]. DOT for tuberculosis is
usually is carried out with once-daily administration of 4 an-
tituberculous drugs (isoniazid, rifampin, pyrazinamide, and
ethambutol), usually 5 days per week for 2 months, followed
by once-daily treatment with isoniazid and rifampin, 3–5 days
per week, for a total of 6–9 months of therapy. Although treat-
ment success rates are variable, available data indicate that,
compared with self-administered tuberculosis therapy, DOT is
associated with decreased incidence of tuberculosis and rates
of drug resistance and with increased rates of sputum conver-
sion and completion of therapy [18–20]. Among persons in-
fected with HIV, DOT has also been associated with improved
survival [20].
By 2001, there were 155 of a total of 210 countries that had
implemented the DOTS strategy for tuberculosis, and an es-
timated 61% of the world’s population lived in parts of coun-
tries providing DOTS programs [21]. WHO and national
guidelines exist to guide and monitor tuberculosis treatment
and its outcomes [16, 17]. Programmatic success is generally
defined as a treatment completion rate of 185%, but this is
often not achieved, and there is wide variability in the success
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in implementing DOTS [16, 17, 22–26]. Some studies even
indicate that observed pill-taking is not superior to self-ad-
ministration. The lack of success is often related to how well
DOTS is implemented. Constraints most commonly identified
that impede successful implementation include lack of qualified
staff, insufficient preparation for program development and
decentralization, lack of contribution of the private sector, in-
adequate health infrastructure, lack of stable drug supplies, and
lack of political commitment. Furthermore, these impediments
have become even more problematic as a consequence of the
HIV/AIDS epidemic [5]. These constraints notwithstanding, in
many developing countries, an established, acceptable, and fa-
miliar DOT infrastructure is available to provide diagnosis and
treatment for patients with tuberculosis. In these programs,
tuberculosis patients receive ongoing clinical care, have secure
access to medications, and are monitored by staff and com-
munity supporters for adherence, side effects, and treatment
outcome. Furthermore, the most successful DOT programs
have supplemented observation of taking of medication with
several other components, including enhanced staff motivation
and patient-centered supportive program elements and en-
hancements [16, 17, 22, 23]. These are often essential for treat-
ment success.
Historically, tuberculosis treatment programs have been sep-
arated from the mainstream of medical care and practice and
have focused specifically on the diagnosis and treatment of
tuberculosis. In the context of the rapidly growing HIV/AIDS
and tuberculosis epidemics, these programs as currently con-
stituted cannot fully address either tuberculosis or HIV disease
[5, 17]. The common ground between tuberculosis and HIV/
AIDS care is being increasingly recognized. At the third meeting
of the WHO Tuberculosis/HIV Working Group in June 2003,
it was concluded that there was clear and achievable benefit of
tuberculosis and HIV/AIDS programs working together to in-
tegrate the care of both diseases [21]. It was noted that program
collaboration was essential and more efficient than completely
separate approaches and that care should be “patient- and not
disease-focused.” Five key points of collaboration emerged from
the meeting: (1) strengthen DOTS and HIV/AIDS care and
prevention, (2) establish national-level tuberculosis/HIVdisease
coordination committees, (3) offer HIV testing and counseling
to all patients with tuberculosis, (4) screen all people attending
HIV/AIDS services for tuberculosis, and (5) offer preventive
therapy for opportunistic infections to those coinfected with
M. tuberculosis and HIV.
Although they are a laudable, essential, and major step for-
ward toward integrating diagnosis and treatment of HIV in-
fection and tuberculosis, these recommendations still fall short
of addressing the need for treatment of both diseases through
the coordinated administration of tuberculosis and antiretro-
viral therapy. To accomplish this, DOT programs for tuber-
culosis could provide an existing, ready-made infrastructure for
the treatment of both tuberculosis and HIV infection and the
concomitant administration of HAART and tuberculosis
medications.
HAART AND DOT
As access to HAART begins to widen in resource-poor coun-
tries, concern exists about the long-term effectiveness of these
regimens, given the potential for inadequate adherence and
subsequent emergence of drug resistance. Issues raised have
included concern that HAART may be problematic in countries
where the costs associated with treatment remain prohibitive
for most and where well-developed health care infrastructures
capable of treatment administration and monitoring are often
limited or nonexistent. These concerns, coupled with undo-
cumented stereotypes about the ability of patients in resource-
poor countries to take antiretroviral medication reliably and
consistently, have been used as arguments to limit the avail-
ability of HAART. Such views ignore the heterogeneity of Af-
rican and other populations and the great desire for treatment
for HIV disease. Indeed, available evidence indicates that rates
of adherence to HIV treatment and therapeutic outcomes do
not differ significantly from those seen in developed countries
[27]. Nevertheless, as therapy becomes more widely available,
difficulties with inadequate adherence to lifelong antiretroviral
therapies can be expected, as has been the experience in de-
veloped countries. It is critically important to anticipate this
and develop and implement strategies for enhancement and
support of adherence. This need has been much too slowly
appreciated in developed countries, with resultant blunting of
therapeutic benefit of HAART and associated rise in the prev-
alence of HIV resistance.
The previously available, more-complicated and more-fre-
quent dosing regimens of antiretrovirals and the need for life-
long treatment have resulted in appropriate concerns that DOT,
as an adherence support measure, although successful for tu-
berculosis treatment, might be unsuitable for treatment of HIV
infection [28, 29]. However, existing preliminary information
supports the utility of DOT for administration of HIV/AIDS
therapy in special settings. In one study, incarcerated, treat-
ment-naive patients enrolled in 4 clinical trials received HAART
by DOT and were compared with patients who received
HAART by self-administration in the community and who were
enrolled in the same trials. The proportion of patients with
declines in HIV RNA levels was significantly higher in the in-
carcerated DOT group, an indication of both the importance
of adherence and the value of this intervention to improve
adherence and therapeutic outcome [30]. The administration
of HAART by DOT has shown very promising results in special
community-based programs as well in developed countries [29,
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31, 32]. In a randomized clinical trial of modified DOT (in
which not all medication doses were administered via DOT),
preliminary results indicate significantly greater decreases in
viral load and increases in CD4+ cells among those randomized
to the DOT arm than among those in the control arm who
received self-administered therapy [32]. Of further and partic-
ular relevance for resource-limited countries, the strategy of
DOT HAART has been successfully used in an innovative com-
munity-based program in Haiti among patients with advanced
HIV disease, although without active tuberculosis [33, 34].
Although the utility of administration of HAART by DOT
requires further study and validation, the availability of potent
once-daily regimens makes this strategy more practical, partic-
ularly because there are existing DOT once-daily regimens for
tuberculosis. Simpler and more easily tolerated antiretroviral
agents and regimens have provided an appealing, direct, and
generalizable intervention to improve adherence. Simpler reg-
imens, including those requiring administration only once
daily, have been associated with equivalent or better therapeutic
outcomes [35, 36]. Recently, more complete understanding of
the pharmacokinetic properties of available NRTIs and the
more favorable pharmacological properties of newer agents has
made once-daily dosing of selected antiretrovirals possible. Al-
though plasma levels and half-lives of the nucleoside reverse-
transcriptase inhibitors (NRTIs) appear too short for once-daily
dosing, the intracellular half-lives of these agents—a more im-
portant measurement of dosing intervals for this class of
drugs—are substantially prolonged. Once-daily dosing is now
possible with many antiretroviral drugs, including the NRTIs
didanosine, stavudine, lamivudine, abacavir, and emtricitabine
and for the nucleotide reverse-transcriptase inhibitor tenofovir.
The nonnucleoside reverse transcriptase inhibitors (NNRTIs)
efavirenz and nevirapine and the protease inhibitor atazanavir
are administered once daily, and low-dose, ritonavir-boosted
protease inhibitor regimens (saquinavir, amprenavir, lopinavir,
and phosamprenavir) can be given once daily. Potent combi-
nations of these individual agents are now possible to con-
struct—creating a broad therapeutic armamentarium of once-
daily regimens. However, the need for use of rifampin-based
antituberculosis regimens limits the antiretroviral options be-
cause of drug interactions. Nonetheless, once-daily HAART
regimens that could be used concomitantly with tuberculosis
therapy include efavirenz plus 2-drug combinations of dida-
nosine, lamivudine, emtricitabine, tenofovir, and stavudine in
extended-release formulation.
Several examples of successful once-daily regimens of rele-
vance for combined therapy with tuberculosis medications have
been reported [37, 38]. In a pilot study among patients with
tuberculosis and HIV infection, once-daily HAART has been
given with tuberculosis medications in a tuberculosis DOT pro-
gram [39]. This study has been successfully carried out in a
large urban tuberculosis clinic in Durban, South Africa. Patients
who were smear-positive for pulmonary tuberculosis and were
receiving tuberculosis treatment were offered HIV testing and
counseling. For those found to be coinfected, a once-daily reg-
imen of 400 mg of didanosine, 300 mg of lamivudine, and 600
mg of efavirenz was provided concomitantly with standard tu-
berculosis therapy. Tuberculosis and HIV medications were
given under observation 5 days per week, and HIV medications
were self-administered on weekends. Of the 20 patients, 17
completed combined standard tuberculosis and anti-HIV ther-
apy. With regard to outcomes of anti-HIV therapy, 16 (80%)
of 20 patients enrolled and 15 (88%) of 17 completing standard
tuberculosis therapy achieved a viral load of !50 copies/mL and
mean increase in CD4+ cell count of 148 cells/mm3. With regard
to tuberculosis outcome, tuberculosis cure was achieved in 17
(89%) of 19 with drug-susceptible tuberculosis. Treatment was
well tolerated, with frequent but mild gastrointestinal, hepatic,
skin, or transient neurological toxicity. A number of important
lessons have emerged from this pilot study that should inform
further evaluation and expansion of this strategy. First, with
careful preparation, the addition of antiretroviral therapy to
the tuberculosis DOT program can be feasible, well-accepted
by staff, and integrated into the daily tuberculosis clinic func-
tions. Second, a relatively small investment in additional staff
and training is necessary. Third, counseling and testing for HIV
infection can be accomplished within a tuberculosis program,
and concerns about patient confidentiality can be successfully
managed. Finally, it seems clear that the introduction of
HAART through an existing tuberculosis DOT program can be
safe and effective. These preliminary findings are encouraging
and warrant rigorous comparison with existing practices, ver-
ification in other settings, and ultimately, with proper attention
to the challenges and opportunities that they raise, consider-
ation of more widespread implementation.
CHALLENGES AND OPPORTUNITIES
Treating tuberculosis and HIV disease concomitantly by means
of the existing tuberculosis DOTS structure may potentially
improve the outcome for each disease. There remain special
challenges as well as opportunities in wider implementation of
this strategy [40, 41]. These include issues related to program
and infrastructure development, patient confidentiality, side ef-
fects and toxicities, pharmacological considerations, durability
of benefit, and array of operational research questions that
require attention and resolution (table 1).
Programmatic and infrastructure issues. To accomplish
integration of tuberculosis and HIV/AIDS care and use of
HAART in the tuberculosis DOT programs, long-held attitu-
dinal and programmatic practices must be altered, because the
current system has been organized around the diagnosis and
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Table 1. Challenges and opportunities of integrating directly observed therapoy (DOT) for HIV infection into existing tuberculosis
DOT programs.
Challenge Opportunity
System organized around diagnosis and treatment of individual
diseases
Integrates care for patient, not individual diseases: “two diseases—
one patient”
Requires resources for enhancing and strengthening tuberculosis
DOT infrastructure and risks potential disruption and overbur-
dening of programs
Uses existing infrastructure, reducing start-up and overall HIV
diagnosis and treatment costs and increases efficiency
May compromise patient confidentiality Provides convenient and efficient site for identifying HIV-positive
patients eligible for HAART
Increases pill burden
May increase side effects and toxicities
May result in problematic pharmacological interactions between
tuberculosis drugs and antiretoroviral drugs
May increase “paradoxical” immune reconstitution reactions
Provides existing structure:
—for promoting HIV adherence
—for monitoring for side effects and toxicities
—for improving HIV therapeutic outcome
Provides only short-term structured HAART because duration of
tuberculosis DOT is limited
Provides initial structured and supervised HAART experience, with
assistance for transition to self-administration
May result in increased rates of tuberculosis treatment failure
and dropout
May have a positive effect on tuberculosis treatment outcomes,
reducing treatment failure and dropout
May improve survival and delay HIV disease progression
treatment of individual diseases. It is well accepted that
strengthening and enhancing existing infrastructure is a more
efficient and cost-effective approach than is development of
entirely new programs and structures. Tuberculosis programs
will require the addition of new resources and personnel, as
well as training to accommodate the necessary increased pro-
gram responsibilities. This will be difficult, but the logic and
efficiency of establishing a single program to treat individual
patients with several comorbid conditions is compelling and
likely to be cost-effective. If the strategy of integration of
HAART into tuberculosis DOT programs is to work on a large
scale, there will be a need for enhanced development and use
of community-based resources as well. Many tuberculosis DOT
programs have relied on community-based treatment sup-
porters to assist with administration and supervision of tuber-
culosis medication. This valuable resource should be extended
to include supervision and assistance with administration of
HIV medications [33, 34]. Community programs and person-
nel represent an underutilized infrastructure in many resource-
limited countries. Although limited in technical and medical
expertise, affected communities often have great personal and
cultural strength and support that can be mobilized. For the
support of long-term administration of medications, this may
be as important as the technical laboratory requirements and
medical expertise often cited as necessary for HIV care.
HIV status disclosure and patient confidentiality. Con-
cerns have been raised that the integration of HIV and tuber-
culosis treatment might create situations in which unantici-
pated or undesired disclosure of HIV status will occur, with
subsequent increased discrimination and stigma. However, if
programs are carefully constructed and staff properly trained,
this can be minimized, and the potential benefits should out-
weigh the dangers. In addition, the availability of treatment is
a powerful motivator for acceptance of HIV testing and coun-
seling and may reduce stigma. In the pilot tuberculosis-HIV
DOT program mentioned above, HIV testing and counseling
was readily accepted, and both tuberculosis and HIV medi-
cations were taken in full view of other patients and staff with-
out incident. The use of tuberculosis programs as sites for
offering HIV testing and counseling will efficiently identify
many who would qualify for and benefit from anti-HIV treat-
ment. It is estimated that 1300,000 people with HIV infection
are given the diagnosis of tuberculosis each year in Africa alone,
and an estimated 400,000 more infected persons are not yet
identified or notified by national programs [21]. If these pa-
tients were offered HIV testing and counseling, they would
likely constitute one of the largest single groups eligible for
HAART and provide an opportunity to bring large numbers
of coinfected people into care and HIV treatment.
Overlapping and additive drug toxicities and side effects.
The treatment of tuberculosis requires intake of 2–4 medica-
tions, and HIV therapy adds an additional 3 medications. Each
of these regimens and their constituent drugs may be associated
with adverse events. These include gastrointestinal intolerance
(associated with isoniazid, rifampin, pyrazinamide, zidovudine,
didanosine, and protease inhibitors), hepatitis (associated with
isoniazid, rifampin, pyrazinamide, nevirapine, efavirenz, and
protease inhibitors), pancreatitis (associated with didanosine),
hypersensitivity reactions (associated with isoniazid, rifampin,
and abacavir), peripheral neuropathy (associated with isoniazid,
didanosine, and stavudine), rash (associated with isoniazid, rif-
ampin, nevirapine, and efavirenz), and neuropsychiatric diffi-
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culties (associated with isoniazid and efavirenz). The combi-
nation of both regimens may result in additive toxicity and
side effects. Some studies suggest that HIV-infected patients
have a higher rate of adverse events when treated for tuber-
culosis, whereas other studies do not support these findings
[42]. Retrospective studies suggest high rates of side effects
when both tuberculosis and HIV treatment regimens are com-
bined [43]. In the small pilot study of combined tuberculosis
and HIV treatment noted above [39], side effects were com-
mon, but generally minor, and did not result in interruption
of therapy. There is a clear need for prospective and uniform
collection of detailed toxicity and side effect data among those
receiving separate and concomitant therapy for tuberculosis
and HIV infection. The concern about additive side effects and
toxicities warrants provider and patient education as well as
careful monitoring for toxicity and tolerability but does not,
in itself, obviate the potential utility of the combined treatment
strategy.
Drug interactions between tuberculosis and antiretroviral
therapy. Drug-drug interactions can result in changes in the
concentrations of one or both of the drugs involved, with con-
sequent reductions in efficacy or increase in toxicity and side
effects. In the case of the antituberculous drugs, the only
HAART-induced interaction of concern is the elevation of ri-
fabutin levels as a consequence of inhibition of cytochrome P-
450 by ritonavir and other protease inhibitors [15, 16]. In re-
source-limited countries, rifabutin is rarely used because of
expense, and this interaction is not seen with the other rifa-
mycins. Most of the clinically relevant drug-drug interactions
involving the antituberculous drugs are due to the effect of the
rifamycins (rifampin, rifabutin, and rifapentine) on the me-
tabolism of antiretrovirals [44–46]. The potentially more prob-
lematic interactions are those induced by rifampin, the most
potent inducer of cytochrome P-450, which is the major path-
way of metabolism of both the protease inhibitors and NNRTIs.
The NRTIs (zidovudine, didanosine, stavudine, lamivudine,
abacavir, and tenofovir) are not metabolized by cytochrome P-
450, and drug interactions with rifampin are not expected or
reported.
Rifampin can reduce therapeutic levels of protease inhibi-
tors by 80%, and therefore these agents are not recommended
for coadministration with rifampin. Exceptions, based on pre-
liminary evidence, indicate that ritonavir alone [47] and the
combination boosted by ritonavir [48] provide acceptable ther-
apeutic levels and therapeutic benefit. Data are currently avail-
able for this ritonavir-boosted protease inhibitor combination
only. It may well be that ritonavir-boosted regimens with other
protease inhibitors will provide similar therapeutic coverage.
Such studies are essential to perform. Rifampin also induces
the metabolism of NNRTIs, reducing levels of efavirenz by 25%
[49] and nevirapine by up to 40% [15, 16]. The former remains
recommended for use with rifampin, whereas there is insuffi-
cient information available to guide proper use of nevirapine.
Opinions differ as to whether efavirenz doses should be rou-
tinely increased to 800 mg daily to compensate for the rifampin-
induced enhanced metabolism of efavirenz. There is wide in-
terpatient variability in efavirenz levels during coadministration
of rifampin [49], and subtherapeutic levels may occur and are
associated with treatment failure [50]. However, unexpectedly
high levels of efavirenz also occur and are associated with un-
desirable side effects, such as dizziness and neuropsychiatric
symptoms. These occur in a substantial proportion of patients
receiving efavirenz [38, 39, 50]. If rifampin and efavirenz are
concomitantly administered in the morning, as is the likely
scenario in a tuberculosis DOT program, these symptoms could
interfere with daily activities and result in decreased adherence
to treatment. On the basis of available data [50], weight ad-
justments of efavirenz might be desirable to both provide ther-
apeutic drug levels and help reduce side effects [47]. Consid-
eration should be given to administering an 800-mg dose to
persons who weight 150 kg and a 600-mg dose to those who
weigh !50 kg. Finally, it is likely that efavirenz levels may vary
over the course of therapy, because the induction mechanisms
of both rifampin and efavirenz change over time. Although
these pharmacological issues are of concern, it is important to
appreciate that available case series regarding coadministration
of rifampin and efavirenz in a standard 600-mg dose note ex-
cellent therapeutic outcomes [39, 51, 52]. Resolution of this
issue requires careful measurement of efavirenz levels over time
in larger numbers of patients receiving both rifampin and efa-
virenz and relating these results to clinical outcome.
Immune reconstitution reactions. The initiation of anti-
retroviral therapy during tuberculosis treatment has been linked
to the development of a “paradoxical” transient worsening of
signs and symptoms of tuberculosis, most likely as a result of
immune reconstitution. The frequency of such events varies
[53–55]. These reactions occur at a median time from the start
of antiretroviral therapy of 22.5 days and are more likely to
occur in patients with larger reductions in viral load and higher
increases in CD4+ cell count [54]. The reactions can complicate
clinical assessment and treatment and can be confused with
adverse drug reactions or the appearance of other opportunistic
diseases. Carefully performed prospective studies with precise
case definitions and proper control populations receiving tu-
berculosis therapy alone are necessary to obtain a better un-
derstanding of the frequency, severity, and clinical consequences
of this entity.
Concerns about durability of benefit. An obvious differ-
ence in tuberculosis and HIV therapy is that the former is time-
limited, whereas the latter is likely to be lifelong. The coad-
ministration of HIV and tuberculosis therapy through the
existing tuberculosis DOT program, although extending to
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completion of tuberculosis treatment, does not directly address
the requirement for more long-term administration of anti-
retroviral therapy. However, this does not obviate the potential
utility of the strategy. This strategy can serve as an entry point
for identification of patients eligible for HIV treatment and
initiation of therapy and the provision of an initial successful
structured experience with antiretrovirals, the benefits of which
may extend well into the subsequent period of long-term self-
administration.
Additional operational research questions. Many addi-
tional questions remain regarding the risks and benefits of the
proposed strategy, as well as programmatic and structural con-
figurations needed for its successful implementation. Opera-
tional research addressing these is crucial and should be directed
toward establishing the effect of the strategy on clinical out-
come, including HIV disease progression and mortality; the
necessary personnel, dose, duration, and location of DOT; and
the needed resources to most efficiently implement such a strat-
egy. These important questions are being addressed in KwaZulu
Natal, South Africa, in a series of demonstration projects in
urban [39] and rural [56] areas and in a large randomized
control trial of concomitant versus sequential tuberculosis and
HAART [57]. The related dual epidemics of HIV/AIDS and
tuberculosis provide the context to explore and answer these
questions and to provide expanded and successful access to
HAART in resource-poor countries, potentially benefiting large
numbers of people living with both diseases.
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